Exclusive Journals Coverage
Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.
Jul 20, 2023
JCO Oncology Practice is shining a spotlight on quality care with a selection of studies aimed at promoting high-quality and equitable care across the cancer trajectory.
Mar 08, 2023
JCO published a special series that features perspectives from a wide range of renowned experts in drug development, including regulators, bioethicists, statisticians, clinician-scientists, and stakeholders in industry and beyond.
Nov 10, 2022
The series illustrates how innovation is making significant strides in securing better access to the technologies and approaches that will have a positive impact on cancer control and health equity across the globe.
Sep 12, 2022
Despite Hispanic/Latinx people making up one-fifth of the population of the United States, there remain significant disparities in cancer care and outcomes in this demographic—a state of affairs that JCO Oncology Practice addressed in a recent special series.
Jul 01, 2022
“In our first 5 years, we’ve impacted both the study and the practice of precision oncology and been able to highlight both successes and remaining challenges in the field, helping us to focus on areas for future study,” said founding editor-in-chief Dr. James M. Ford.
Mar 08, 2022
Dr. Pamela Kunz discusses her editorial priorities at JCO and the collaborative efforts that will advance equity in the selection of meeting abstracts.
Feb 22, 2022
Dr. Peppercorn will begin serving as the editor designee of JCO OP on March 1, 2022, and as editor-in-chief on September 1.
Jan 14, 2022
A new payment model in radiation oncology takes effect in January 2022 and will make significant strides towards transitioning Medicare reimbursement models into an episode-based payment system for certain cancers.
Sep 01, 2021
A novel approach to address financial toxicity, published in JCO Oncology Practice, features the first Financial Toxicity Tumor Board developed by the Levine Cancer Institute in North Carolina.
Aug 06, 2021
When Dr. Bosserman began her tenure as editor-in-chief in January 2019, she expanded the publication’s priorities of care delivery and quality improvement while addressing issues of equity and value.
Pages
